Additional efforts to broaden the applicability of T-DXd to a larger population, such as for HR+/HER2-low BC after the progress of endocrine therapy (ClinicalTrials.gov identifier: NCT04494425), are underway [48]. The gene discussed is ERBB2; the disease is breast cancer.